NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Check the time stamp on this data. Updated AI-Generated Signals for Keros Therapeutics Inc. (KROS) available here: KROS. Type a few symbols and Take a Trial. The signals for these will appear ...

Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Keros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% ...

Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should Keros Therapeutics (NASDAQ:KROS) shareholders be worried about its cash burn?

Oppenheimer has recently reiterated Keros Therapeutics Inc (KROS) stock to Outperform rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 16, 2024, Guggenheim had ...

Keros Therapeutics Inc (KROS) stock saw a decline, ending the day at $11.39 which represents a decrease of $-0.02 or -0.18% from the prior close of $11.41. The stock opened at $11.31 and touched a low ...

Subscribers also receive market analysis, stock correlation tools, macroeconomic observations, timing tools, and protection from market crashes using Evitar Corte.

Keros Therapeutics (NASDAQ:KROS – Get Free Report) had its target price cut by equities research analysts at Oppenheimer from ...

Keros Therapeutics (NASDAQ:KROS – Free Report) had its price target lowered by Piper Sandler from $40.00 to $15.00 in a research report report published on Friday,Benzinga reports. The firm currently ...

Keros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% over the past four weeks, the stock looks well positioned for a trend ...